Legal News

EMA waives scientific advice fees for developing medicines for rare diseases

Published on: 23 June 2020
Published by LNB News

LNB News 23/06/2020

Document Information

Issue Date: 23 June 2020

Published Date: 23 June 2020

Jurisdiction(s): United Kingdom

Article summary

The European Medicines Agency (EMA) has waived all fees for scientific advice for academia developing medicines for rare diseases. The decision to waive fees was brought on by feedback from academia that fees for protocol assistance represents a barrier to engaging with the EMA. The EMA has included academia in the list of organisations eligible for free protocol assistance as of 19 June 2020. Eligible applicants include ‘public or private higher education establishments awarding academic degrees, public or private non-profit research organisations whose primary mission is to pursue research, and international European interest organisations.’

Popular documents